Federation Des Caisses Desjardins Du Quebec Calliditas Therapeutics Ab Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$20.04 - $25.66 $79,859 - $102,255	3,985 New	3,985 $83.7 Million
Q3 2023 Aug 14, 2024	BUY	$15.68 - $20.38 $7,056 - $9,171	450 Added 22.11%	2,485 $45.4 Million
Q2 2023 Aug 14, 2024	BUY	$15.7 - $25.61 $7,850 - $12,805	500 Added 32.57%	2,035 $32.2 Million
Q1 2023 Aug 14, 2024	BUY	$16.8 - $25.24 $8,400 - $12,620	500 Added 48.31%	1,535 $36.8 Million
Q1 2022 Aug 14, 2024	BUY	$15.14 - $25.55 $15,669 - $26,444	1,035 New	1,035 $19.8 Million
Q3 2021 Aug 30, 2024	BUY	$21.03 - $33.19 $13,143 - $20,743	625 Added 152.44%	1,035 $22.4 Million
Q2 2021 Aug 30, 2024	BUY	$26.02 - $31.17 $10,668 - $12,779	410 New	410 $12.1 Million

Others Institutions Holding CALT

# of Institutions

Shares Held

20.3K

Call Options Held

Put Options Held

View Full List

About Calliditas Therapeutics AB

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

More about CALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account